← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicstaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleOBI Pharma, IncPhase 2

OBI-902 (OBI-902)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOBI Pharma, IncPhase 2

OBI-992 (OBI-992)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOBI Pharma, IncPhase 2

OBI-999 (OBI-999)

Locally Advanced Solid Tumor · Locally Advanced Solid Tumor

#LocallyAdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 1상태 DISCONTINUED
ADCBiologicstaleOxford BioTherapeutics LtdPhase 1

OBT076, a CD205-directed antibody-drug conjugate (OBT076, a CD205-directed antibody-drug conjugate)

Solid Tumor · CD20

#CD20#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleOrum Therapeutics USA, Inc.Phase 1

ORM-5029 (ORM-5029)

HER2-positive Breast Cancer; HER-2 Protein Overexpression · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 DISCONTINUED
ADCBiologicstaleThe Affiliated Hospital of Xuzh…Phase 2

Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT (Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleEric Thompson, M.D.Phase 1

PEP-CMV: Component A (PEP-CMV: Component A)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleEric Thompson, M.D.Phase 1

PEP-CMV: Component B (PEP-CMV: Component B)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstalePfizerPhase 1

PF-08046033 (PF-08046033)

Non-Small-Cell Lung; Esophageal Cancer · Non-Small-Cell Lung

#Non-Small-CellLung#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstalePfizerPhase 1

PF-08046876 (PF-08046876)

Advanced/Metastatic Solid Tumors; Bladder Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
임상시험 1상태 RECRUITING
ADCBiologicstalePheon TherapeuticsPhase 1

PHN-010 (PHN-010)

Lung Cancer; Colon Cancer · Lung Cancer

#LungCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstalePheon TherapeuticsPhase 1

PHN-012 (PHN-012)

Colon Cancer; Pancreatic Cancer · Colon Cancer

#ColonCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
ADCBiologicstaleNorthwestern UniversityPhase 1

PI3K inhibitor BYL719 (PI3K inhibitor BYL719)

HER2-positive Breast Cancer; Recurrent Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 4%임상시험 1상태 ACTIVE
ADCBiologicstalePrimelink BioTherapeitics(ShenZ…Phase 1

PLB-002 (PLB-002)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

POLA-Hi-CHP+orelabrutinib (POLA-Hi-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleThe First Affiliated Hospital w…Phase 2

POLA-R-CHP+Zanubrutinib (POLA-R-CHP+Zanubrutinib)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleOu Bai, MDPhase 2

POLA-R-CHP+orelabrutinib (POLA-R-CHP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING

47 / 54 페이지

← 이전다음 →